The Effects of Sotagliflozin in Type 1 Diabetes on Clinical Markers Associated With Cardiorenal Protection: An Exploratory Analysis of inTandem3

Diabetes Care. 2023 Jul 1;46(7):e133-e135. doi: 10.2337/dc23-0129.

Vikas S Sridhar^{1

2

3}, Hiddo J L Heerspink⁴, Michael J Davies⁵, Phillip Banks⁵, Manon Girard⁵, Satish K Garg⁶, David Z I Cherney^{1

2

3}

¹ 1Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.
² 2Division of Nephrology, Department of Medicine, University Health Network, Toronto, Ontario, Canada.
³ 3Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
⁴ 4Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, the Netherlands.
⁵ 5Lexicon Pharmaceuticals, Inc., The Woodlands, TX.
⁶ 6Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora, CO.

No abstract available

Publication types

(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol
Hypoglycemic Agents
Glycosides
Biomarkers